Evommune’s G-protein coupled receptor X2 (MRGPRX2) antagonist has failed another phase 2 trial, ending the biotech’s final chance at developing the therapy for any itchy diseases.
The drug, called EVO756, had been under investigation in 121 adults with moderate-to-severe atopic dermatitis (AD) compared with placebo. The trial failed to meet its primary goal of showing improvement in eczema area or severity from baseline at Week 12, and all secondary goals, in the phase 2 trial.
Compounding Failures and Market Reaction
There was another setback for EVO756 last month when the drug failed to show any efficacy in patients’ urticaria at any of the dosage levels tested. The outcome of that lowered expectations for EVO756 to be worth a place in the AD study.
Ahead of the news, however, investors still sank the price of Evommune’s shares by 18% as a result of the study. Its stock closed at $10.70 at the close of business, falling from $13.08 at the close a few days back.
Pivot to Migraine Prevention
Evommune does not plan to try to develop EVO756 for AD, but the biotech hasn’t written it off just yet. The biotech said it will continue with a phase 2b trial to prevent migraine with the asset.
Evommune’s Chief Medical Officer Eugene Bauer said in the Sept. release that he was disappointed the trial failed to meet its primary endpoint, especially since there is a need for new options for patients with AD. 9 release.
“EVO756 was safe and generally well tolerated with a safety profile similar to previous studies, and continues to be evaluated for use in migraine prophylaxis,” Bauer continued.
Last month, William Blair analysts wrote in a note to investors that the migraine opportunity for EVO756 was “higher risk, but definitely intriguing and with significant upside.”
Future Pipeline Focus and Financial Outlook
While EVO756 is still on Evommune’s development pipeline, the company is focusing on EVO301, an IL-18BP fusion protein that obtained success in a February phase 2 study of eczema.
Evommune CEO Luis Peña acknowledged that the EVO756 study didn’t meet the expectations that both the Evo and the AD community had, but noted that EVO301 is set to move to a phase 2b study in mid-2027.
We have a very strong balance sheet going into 2029, and we’re continuing to pursue a set of programs we have that we want to broadly address chronic inflammatory diseases,” Peña continued.
Evommune has abandoned development of EVO756 for atopic dermatitis after the experimental MRGPRX2 antagonist failed to meet its primary endpoint in a Phase 2b study. The setback follows an earlier Phase 2b failure in chronic spontaneous urticaria, marking the second major efficacy disappointment for the program in 2026.
The latest Evommune study evaluated EVO756 in 121 adults with moderate-to-severe atopic dermatitis. The trial failed to demonstrate a meaningful improvement in eczema severity at Week 12, and the drug also missed its secondary endpoints. Reports indicated that no meaningful benefit on itch was observed.
Evommune Faces Second Major Trial Failure
The Evommune setback comes only months after EVO756 failed to demonstrate efficacy in chronic spontaneous urticaria. That earlier Phase 2b trial involved 160 patients and failed its primary endpoint across all tested doses.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
